跳转至内容
Merck
CN
所有图片(1)

主要文件

G005540

HPLC Analysis of Dermorphin in Horse Plasma on Ascentis® Express F5 after SPE with HybridSPE®

application for HPLC, application for SPE

登录查看公司和协议定价


About This Item

技术

HPLC: suitable
solid phase extraction (SPE): suitable

试验参数

sample preparation: SPE (Solid Phase Extraction)
sample/matrix: horse plasma spiked at 10 μg/mL
SPE tube/cartridge: [TM"HybridSPE"]-Phospholipid Plate, 50mg/96-Well (575656-U)
sample addition: 3:1, (1% formic acid in acetonitrile); plasma
column: Ascentis Express F5, 10 cm x 2.1 mm I.D., 2.7 μm particles (53569-U)
mobile phase: [A] acetonitrile [B] 20 mM ammonium formate; (90:10, A:B); pH 4.5 with formic acid, after mixing A & B
flow rate: 0.4 mL/min
pressure: 1305 psi (90 bar)
column temp.: 35 °C
detector: MS, ESI(+), TIC, m/z 100-1000
injection: 1 μL

适用性

application for HPLC
application for SPE

应用

forensics and toxicology

分析说明

Dermorphin is a natural heptapeptide opioid. Because of poor recovery from horse plasma following protein precipitation, alternate methods of extraction are sought. While the HybridSPE protocol successfully removes proteins and phospholipids, dermorphin solubility in plasma remains a limitation. Dermorphin is effectively retained on the pentafluorophenyl phase under aqueous normal phase conditions.

法律信息

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

流动相组分


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门